Document | Year | Terms |
---|---|---|
04/02/2021 - 10:30 pm DBV Technologies Announces Appointment of Timothy E. Morris to Board of DirectorsDownload PDF (153 KB) | ||
04/02/2021 - 12:30 am Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021Download PDF (160 KB) | ||
03/26/2021 - 9:30 pm DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General MeetingDownload PDF (198 KB) | ||
03/17/2021 - 11:30 pm DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration DocumentDownload PDF (181 KB) | ||
03/12/2021 - 10:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021Download PDF (160 KB) | ||
03/11/2021 - 10:30 pm DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business DevelopmentsDownload PDF (294 KB) | ||
03/05/2021 - 10:30 pm DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences ConferenceDownload PDF (133 KB) | ||
03/04/2021 - 12:00 am DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial ResultsDownload PDF (200 KB) | ||
03/01/2021 - 7:30 am DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021Download PDF (200 KB) | ||
02/24/2021 - 7:30 am DBV Technologies to Participate in Upcoming AAAAI 2021 CongressDownload PDF (247 KB) | ||
02/22/2021 - 7:30 am DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal OfficerDownload PDF (195 KB) | ||
02/19/2021 - 7:30 am DBV Technologies to Participate in SVB Leerink Global Partners Healthcare ConferenceDownload PDF (132 KB) | ||
02/11/2021 - 10:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021Download PDF (160 KB) | ||
01/29/2021 - 10:30 pm Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFDownload PDF (191 KB) | ||
01/14/2021 - 10:30 pm DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 YearsDownload PDF (215 KB) | ||
01/07/2021 - 7:30 am DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring ProcessDownload PDF (155 KB) | ||
01/05/2021 - 10:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020Download PDF (160 KB) | ||
12/15/2020 - 10:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020Download PDF (160 KB) | ||
11/24/2020 - 7:30 am DBV Technologies Announces Leadership ChangesDownload PDF (141 KB) | ||
11/11/2020 - 4:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020Download PDF (161 KB) | ||
11/10/2020 - 7:30 am DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020Download PDF (255 KB) | ||
11/09/2020 - 7:30 am DBV Technologies to Participate in Upcoming Investor ConferencesDownload PDF (177 KB) | ||
11/02/2020 - 7:30 am DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines AgencyDownload PDF (176 KB) | ||
10/30/2020 - 7:30 am DBV Technologies Reports September 30, 2020 Cash PositionDownload PDF (187 KB) | ||
10/08/2020 - 10:01 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020Download PDF (160 KB) | ||
09/15/2020 - 10:30 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020Download PDF (160 KB) | ||
09/09/2020 - 7:30 am DBV Technologies Announces Leadership ChangesDownload PDF (151 KB) | ||
09/02/2020 - 10:30 pm DBV Technologies to Participate in Multiple September Investor ConferencesDownload PDF (180 KB) | ||
08/12/2020 - 10:01 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020Download PDF (160 KB) | ||
08/04/2020 - 7:30 am DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 YearsDownload PDF (437 KB) | ||
07/31/2020 - 7:30 am | Finance DBV Technologies Reports First Half 2020 Financial ResultsDownload PDF (437 KB) | ||
07/20/2020 - 10:01 pm Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFDownload PDF (393 KB) | ||
07/15/2020 - 10:01 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020Download PDF (160 KB) | ||
07/10/2020 - 3:03 pm DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical ImmunologyDownload PDF (283 KB) | ||
06/26/2020 - 8:30 am DBV Technologies Provides Operational and Business UpdateDownload PDF (223 KB) | ||
06/11/2020 - 10:01 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020Download PDF (160 KB) | ||
06/04/2020 - 10:30 pm DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020Download PDF (180 KB) | ||
06/02/2020 - 10:30 pm DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceDownload PDF (169 KB) | ||
05/12/2020 - 10:01 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020Download PDF (160 KB) | ||
04/30/2020 - 10:01 pm DBV Technologies Reports March 31, 2020 Cash PositionDownload PDF (130 KB) | ||
04/20/2020 - 10:01 pm DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General MeetingDownload PDF (201 KB) | ||
04/15/2020 - 10:04 pm | General Assembly Ordinary and Extraordinary General Meeting of April 20, 2020Download PDF (144 KB) | ||
04/15/2020 - 12:00 pm | Corporate Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
04/10/2020 - 10:01 pm Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 PandemicDownload PDF (188 KB) | ||
03/30/2020 - 10:01 pm | General Assembly Ordinary and Extraordinary General Meeting of April 20, 2020Download PDF (165 KB) | ||
03/20/2020 - 9:15 pm DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-FDownload PDF (122 KB) | ||
03/17/2020 - 9:00 pm Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020Download PDF (78 KB) | ||
03/16/2020 - 9:30 pm DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 YearsDownload PDF (153 KB) | ||
03/16/2020 - 11:40 am | General Assembly Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (50 KB) | ||
03/04/2020 - 10:30 pm DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business UpdateDownload PDF (211 KB) | ||
03/04/2020 - 10:01 pm DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global OfferingDownload PDF (193 KB) | ||
03/02/2020 - 7:30 am DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)Download PDF (212 KB) | ||
02/24/2020 - 10:00 pm DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020Download PDF (220 KB) | ||
02/21/2020 - 3:30 pm DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in ChildrenDownload PDF (168 KB) | ||
02/10/2020 - 10:00 pm DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare ConferenceDownload PDF (146 KB) | ||
02/07/2020 - 2:00 am Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020Download PDF (51 KB) | ||
02/06/2020 - 10:01 pm DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations OfficerDownload PDF (167 KB) | ||
02/04/2020 - 10:30 pm DBV Technologies Announces Closing of Global OfferingDownload PDF (248 KB) | ||
01/30/2020 - 7:30 am DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary SharesDownload PDF (172 KB) | ||
01/29/2020 - 10:05 pm DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash PositionDownload PDF (171 KB) | ||
01/15/2020 - 10:00 pm Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFDownload PDF (203 KB) | ||
01/14/2020 - 10:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
01/08/2020 - 10:30 pm DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut AllergyDownload PDF (175 KB) | ||
01/02/2020 - 10:30 pm DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial OfficerDownload PDF (169 KB) | ||
12/10/2019 - 11:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
11/19/2019 - 11:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
11/05/2019 - 10:30 pm DBV Technologies to Present at the Stifel 2019 Healthcare ConferenceDownload PDF (130 KB) | ||
10/24/2019 - 10:01 pm DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019Download PDF (182 KB) | ||
10/16/2019 - 12:30 pm | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
10/15/2019 - 10:30 pm DBV Technologies Announces Closing of Global OfferingDownload PDF (212 KB) | ||
10/10/2019 - 7:30 am DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)Download PDF (219 KB) | ||
10/09/2019 - 7:30 am DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary SharesDownload PDF (190 KB) | ||
10/08/2019 - 10:15 pm | Corporate DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash PositionDownload PDF (182 KB) | ||
10/04/2019 - 5:45 pm DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut AllergyDownload PDF (152 KB) | ||
10/02/2019 - 10:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (87 KB) | ||
09/19/2019 - 10:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
08/07/2019 - 10:05 pm DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut AllergyDownload PDF (169 KB) | ||
08/01/2019 - 7:30 am | Finance DBV Technologies Reports First Half 2019 Financial ResultsDownload PDF (240 KB) | ||
07/18/2019 - 7:30 am Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year ReportDownload PDF (229 KB) | ||
07/12/2019 - 12:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
06/26/2019 - 7:30 am DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical OfficerDownload PDF (179 KB) | ||
06/11/2019 - 2:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (87 KB) | ||
06/03/2019 - 7:30 am DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (158 KB) | ||
06/01/2019 - 2:00 pm DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019Download PDF (162 KB) | ||
05/24/2019 - 10:30 pm DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of DirectorsDownload PDF (137 KB) | ||
05/14/2019 - 7:30 am DBV Technologies Announces Departure of Deputy CEO David SchilanskyDownload PDF (163 KB) | ||
05/03/2019 - 10:30 pm | General Assembly Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General MeetingDownload PDF (156 KB) | ||
05/02/2019 - 7:30 am | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (219 KB) | ||
04/30/2019 - 7:30 am | Finance DBV Technologies Reports March 31, 2019 Cash PositionDownload PDF (139 KB) | ||
04/10/2019 - 5:00 pm | Corporate Information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (81 KB) | ||
04/08/2019 - 10:30 pm | Finance DBV Technologies Announces Closing of Global OfferingDownload PDF (184 KB) | ||
04/08/2019 - 5:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (87 KB) | ||
04/05/2019 - 7:30 am | Finance DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)Download PDF (133 KB) | ||
04/04/2019 - 8:00 am | Finance DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary SharesDownload PDF (162 KB) | ||
04/03/2019 - 10:10 pm | Corporate | Finance DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary SharesDownload PDF (172 KB) | ||
04/01/2019 - 11:00 pm | Finance DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-FDownload PDF (124 KB) | ||
03/06/2019 - 7:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
03/05/2019 - 10:10 pm DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational UpdateDownload PDF (160 KB) | ||
03/05/2019 - 7:30 am DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of DirectorsDownload PDF (144 KB) | ||
03/01/2019 - 7:30 am DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (156 KB) | ||
02/22/2019 - 5:00 pm DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical AssociationDownload PDF (187 KB) | ||
02/13/2019 - 10:07 pm DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of AgeDownload PDF (142 KB) | ||
02/08/2019 - 4:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (87 KB) | ||
02/04/2019 - 10:00 pm DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019Download PDF (190 KB) | ||
02/01/2019 - 7:30 am | Conferences DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare ConferenceDownload PDF (124 KB) | ||
01/17/2019 - 7:30 am Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFDownload PDF (148 KB) | ||
01/11/2019 - 5:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (87 KB) | ||
01/03/2019 - 7:30 am DBV Technologies Expands and Strengthens Leadership TeamDownload PDF (644 KB) | ||
12/19/2018 - 11:00 pm DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of AgeDownload PDF (170 KB) | ||
12/12/2018 - 7:30 am DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018Download PDF (576 KB) | ||
12/06/2018 - 8:00 pm | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
11/20/2018 - 7:30 am DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic ChildrenDownload PDF (415 KB) | ||
11/16/2018 - 7:30 am DBV Technologies Appoints Daniel Tassé as Chief Executive OfficerDownload PDF (451 KB) | ||
11/09/2018 - 7:30 am DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI MeetingDownload PDF (409 KB) | ||
11/07/2018 - 6:30 pm | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB) | ||
10/30/2018 - 7:30 am | Finance DBV Technologies Reports September 30, 2018 Cash PositionDownload PDF (376 KB) | ||
10/26/2018 - 7:30 am | Clinical DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic ToddlersDownload PDF (551 KB) | ||
10/22/2018 - 7:30 am | Corporate DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug AdministrationDownload PDF (351 KB) | ||
10/09/2018 - 5:00 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (256 KB) | ||
09/25/2018 - 7:30 am DBV Technologies to Present at the Cantor Global Healthcare ConferenceDownload PDF (296 KB) | ||
09/12/2018 - 7:30 am DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic ToddlersDownload PDF (434 KB) | ||
09/07/2018 - 6:00 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (256 KB) | ||
09/07/2018 - 7:30 am | Finance DBV Technologies Reports First Half 2018 Financial ResultsDownload PDF (517 KB) | ||
09/05/2018 - 7:30 am | Science DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of ImmunologyDownload PDF (430 KB) | ||
08/31/2018 - 7:30 am DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (325 KB) | ||
07/27/2018 - 7:30 am | Finance DBV Technologies Reports June 30, 2018 Cash PositionDownload PDF (375 KB) | ||
07/26/2018 - 7:18 am DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial OfficerDownload PDF (419 KB) | ||
07/19/2018 - 12:30 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (256 KB) | ||
07/13/2018 - 7:30 am Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHFDownload PDF (373 KB) | ||
06/26/2018 - 5:24 pm | Corporate Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (55 KB) | ||
06/22/2018 - 9:53 pm DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General CounselDownload PDF (368 KB) | ||
06/11/2018 - 5:00 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (256 KB) | ||
06/05/2018 - 7:30 am | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (313 KB) | ||
06/01/2018 - 7:30 am | General Assembly Annual General Meeting, June 22, 2018Procedures for Obtaining Preparatory Documents for the General Meeting | ||
05/29/2018 - 7:00 pm | General Assembly Annual General Meeting, June 22, 2018Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018 | ||
05/29/2018 - 7:30 am | Medical Congresses DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018Download PDF (428 KB) | ||
05/16/2018 - 7:30 am | Corporate DBV Technologies Announces Appointment of Michel de Rosen to its Board of DirectorsDownload PDF (346 KB) | ||
05/14/2018 - 6:30 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (256 KB) | ||
05/14/2018 - 2:30 pm | Corporate DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness WeekDownload PDF (356 KB) | ||
05/08/2018 - 7:30 am | Medical Congresses DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI MeetingDownload PDF (460 KB) | ||
05/01/2018 - 7:30 am | Corporate DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (306 KB) | ||
04/27/2018 - 7:30 am | Finance DBV Technologies Reports March 31, 2018 Cash PositionDownload PDF (316 KB) | ||
04/05/2018 - 6:00 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (156 KB) | ||
04/03/2018 - 7:30 am | Conferences DBV Technologies to Attend the 11th Kempen Life Sciences ConferenceDownload PDF (289 KB) | ||
03/26/2018 - 10:00 pm | Finance DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Shares in Global OfferingDownload PDF (321 KB) | ||
03/23/2018 - 9:00 pm | Finance DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesDownload PDF (324 KB) | ||
03/21/2018 - 8:14 am | Finance DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary SharesDownload PDF (458 KB) | ||
03/20/2018 - 9:01 pm | Finance DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary SharesDownload PDF (479 KB) | ||
03/16/2018 - 9:30 pm | Corporate | Finance DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-FDownload PDF (319 KB) | ||
03/14/2018 - 2:30 am | Finance DBV Technologies Reports Full Year 2017 Financial ResultsDownload PDF (398 KB) | ||
03/07/2018 - 1:30 am | Conferences DBV Technologies to Present at the Barclays Global Healthcare ConferenceDownload PDF (314 KB) | ||
02/28/2018 - 9:07 pm | Corporate Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (156 KB) | ||
02/26/2018 - 10:45 pm | Clinical DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic PatientsDownload PDF (1 MB) | ||
02/20/2018 - 7:30 am | Finance DBV Technologies Reports December 31, 2017 Cash PositionDownload PDF (924 KB) | ||
02/14/2018 - 7:30 am | Clinical DBV Technologies Provides Update on Regulatory Progress for Viaskin PeanutDownload PDF (1,017 KB) | ||
02/13/2018 - 2:16 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (158 KB) | ||
02/12/2018 - 3:00 pm | Science DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint CongressDownload PDF (1 MB) | ||
02/01/2018 - 7:30 am | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (643 KB) | ||
01/16/2018 - 7:30 am | Finance Half-Year Report on the DBV Technologies Liquidity Contract with NatixisDownload PDF (643 KB) | ||
01/12/2018 - 4:08 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (159 KB) | ||
01/03/2018 - 7:30 am | Conferences DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare ConferenceDownload PDF (642 KB) | ||
12/22/2017 - 12:30 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (159 KB) | ||
11/19/2017 - 8:49 pm DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic PatientsDownload PDF (1 MB) | ||
10/20/2017 - 8:55 pm DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut- Allergic Patients Four to 11 Years of AgeDownload PDF (1 MB) | ||
10/12/2017 - 8:48 pm DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin PeanutDownload PDF (1,018 KB) | ||
10/03/2017 - 5:58 pm | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (159 KB) | ||
09/05/2017 - 7:42 pm Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (158 KB) | ||
09/01/2017 - 7:43 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (709 KB) | ||
08/29/2017 - 7:44 pm | Clinical DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin PeanutDownload PDF (323 KB) | ||
08/02/2017 - 7:57 pm | Clinical DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of AgeDownload PDF (1,023 KB) | ||
07/28/2017 - 7:58 pm | Finance DBV Technologies Reports First Half 2017 Financial ResultsDownload PDF (1,015 KB) | ||
07/07/2017 - 8:00 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (57 KB) | ||
07/05/2017 - 8:01 pm | Finance Half-Year Report on the DBV Technologies Liquidity Contract with NatixisDownload PDF (111 KB) | ||
06/17/2017 - 8:32 pm | Science DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI CongressDownload PDF (1 MB) | ||
06/15/2017 - 8:34 pm | General Assembly DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General MeetingDownload PDF (926 KB) | ||
06/12/2017 - 5:07 pm DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General MeetingDownload PDF (926 KB) | ||
06/01/2017 - 8:38 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (925 KB) | ||
05/12/2017 - 5:29 pm | Corporate | Finance Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General MeetingDownload PDF (158 KB) | ||
05/08/2017 - 9:27 pm | Science DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn’s Disease at Digestive Disease Week 2017Download PDF (1,020 KB) | ||
05/02/2017 - 5:32 pm | Conferences | Finance DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (928 KB) | ||
04/28/2017 - 9:29 pm | Finance DBV Technologies Reports March 31, 2017 Cash PositionDownload PDF (927 KB) | ||
04/05/2017 - 9:31 pm | Conferences DBV Technologies to Attend the 10th Kempen Life Sciences ConferenceDownload PDF (643 KB) | ||
04/05/2017 - 9:31 pm | Conferences Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (159 KB) | ||
03/30/2017 - 9:32 pm | Clinical | Corporate DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster VaccinationDownload PDF (355 KB) | ||
03/22/2017 - 11:30 pm | Corporate | Finance DBV Technologies Announces Filing of its 2016 “Document de Référence” and Annual Report on Form 20-FDownload PDF (1,008 KB) | ||
03/15/2017 - 7:30 am | Finance DBV Technologies Reports Full Year 2016 Financial ResultsDownload PDF (194 KB) | ||
03/10/2017 - 7:30 am | Clinical | Product Candidates DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic ChildrenDownload PDF (1 MB) | ||
03/07/2017 - 2:47 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (158 KB) | ||
03/05/2017 - 9:45 pm | Clinical | Conferences Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic ChildrenDownload PDF (1 MB) | ||
03/01/2017 - 7:30 am | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (927 KB) | ||
02/20/2017 - 7:30 am | Finance DBV Technologies Reports December 31, 2016 Cash PositionDownload PDF (927 KB) | ||
02/10/2017 - 10:41 pm | Conferences | Corporate | Science DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®Download PDF (1 MB) | ||
02/05/2017 - 11:34 am | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (155 KB) | ||
02/03/2017 - 7:30 am | Clinical | Product Candidates DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic EsophagitisDownload PDF (1,020 KB) | ||
01/26/2017 - 7:30 am | Conferences DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare ConferenceDownload PDF (927 KB) | ||
01/09/2017 - 7:30 am | Corporate | Finance DBV Technologies Announces Financial Calendar 2017Download PDF (121 KB) | ||
01/04/2017 - 5:38 pm | Finance DBV Technologies Presents its Half-year Statement of the Liquidity ContractDownload PDF (940 KB) | ||
01/04/2017 - 5:10 pm | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (155 KB) | ||
12/07/2016 - 10:57 am | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (155 KB) | ||
11/17/2016 - 7:30 am | Clinical | Product Candidates DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against PertussisDownload PDF (347 KB) | ||
11/16/2016 - 10:57 am | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (155 KB) | ||
11/12/2016 - 1:30 am | Science DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology MeetingDownload PDF (1 MB) | ||
11/10/2016 - 3:00 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (931 KB) | ||
11/08/2016 - 3:01 pm | Clinical | Product Candidates DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic PatientsDownload PDF (150 KB) | ||
11/03/2016 - 3:03 pm | Finance DBV Technologies Reports September 30, 2016 Cash PositionDownload PDF (928 KB) | ||
10/26/2016 - 3:04 pm | Clinical | Product Candidates DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical ImmunologyDownload PDF (1 MB) | ||
10/24/2016 - 3:05 pm | Clinical | Product Candidates Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to PeanutDownload PDF (1 MB) | ||
10/17/2016 - 3:06 pm | Corporate | Finance Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (155 KB) | ||
09/21/2016 - 3:07 pm | Product Candidates DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein AllergyDownload PDF (1 MB) | ||
09/06/2016 - 3:08 pm | Clinical | Partnership DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster VaccinationDownload PDF (362 KB) | ||
09/01/2016 - 3:09 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (941 KB) | ||
08/01/2016 - 3:10 pm | Clinical DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut AllergyDownload PDF (1 MB) | ||
07/28/2016 - 7:30 am | Finance DBV Technologies Reports Interim Financial Results for the First Half of 2016Download PDF (205 KB) | ||
07/11/2016 - 3:12 pm | Finance Half year update on the DBV Technologies liquidity agreementDownload PDF (923 KB) | ||
07/05/2016 - 3:13 pm | Corporate DBV Technologies Proudly Welcomes Dr. Lucia Septién as Chief Medical OfficerDownload PDF (1,023 KB) | ||
06/27/2016 - 3:14 pm | Clinical DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic ChildrenDownload PDF (1,022 KB) | ||
06/21/2016 - 8:31 pm | General Assembly DBV Announced Results of its 2016 Annual Meeting of ShareholdersDownload PDF (927 KB) | ||
06/21/2016 - 3:15 pm | General Assembly DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys FerrereDownload PDF (1 MB) | ||
06/16/2016 - 3:17 pm | Conferences DBV Technologies to Present at the JMP Securities Life Sciences ConferenceDownload PDF (640 KB) | ||
06/15/2016 - 3:17 pm | Product Candidates | Science Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment ProgressionDownload PDF (1,023 KB) | ||
06/13/2016 - 3:18 pm | Science DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against AnaphylaxisDownload PDF (1 MB) | ||
06/07/2016 - 3:19 pm | Corporate DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory BoardDownload PDF (1,023 KB) | ||
06/01/2016 - 3:20 pm | Conferences | Science DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food AllergiesDownload PDF (2 MB) | ||
05/31/2016 - 3:21 pm | Partnership DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk AllergyDownload PDF (1 MB) | ||
05/30/2016 - 8:30 pm | General Assembly Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the AssemblyDownload PDF (943 KB) | ||
05/20/2016 - 3:23 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (941 KB) | ||
04/29/2016 - 3:24 pm | Finance DBV Technologies Reports March 31, 2016 Cash PositionDownload PDF (930 KB) | ||
04/28/2016 - 3:25 pm | Corporate DBV Technologies Announces Filing of 2015 “Document de Référence” and 2015 Annual Report on Form 20-FDownload PDF (1,010 KB) | ||
04/27/2016 - 3:26 pm | Conferences DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (941 KB) | ||
04/11/2016 - 3:27 pm | Science DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous ImmunotherapyDownload PDF (1 MB) | ||
04/07/2016 - 3:28 pm | Finance DBV Technologies Reports Full Year 2015 Financial ResultsDownload PDF (1 MB) | ||
03/06/2016 - 3:29 pm | Product Candidates Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and ComplianceDownload PDF (2 MB) | ||
03/04/2016 - 3:30 pm | Product Candidates DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and EfficacyDownload PDF (1 MB) | ||
03/01/2016 - 3:31 pm | Conferences DBV Technologies to Attend Upcoming Investor Conferences and EventsDownload PDF (937 KB) | ||
02/25/2016 - 3:32 pm | Product Candidates DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin® PeanutDownload PDF (1 MB) | ||
02/15/2016 - 3:33 pm | Finance DBV Technologies Reports December 31, 2015, Cash PositionDownload PDF (925 KB) | ||
02/10/2016 - 3:34 pm | Conferences | Finance DBV Technologies to Present New Data at the 2016 AAAAI Annual MeetingDownload PDF (1 MB) | ||
02/08/2016 - 3:35 pm | Conferences DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare ConferenceDownload PDF (642 KB) | ||
01/26/2016 - 3:36 pm | Corporate DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North AmericaDownload PDF (1,013 KB) | ||
01/08/2016 - 3:38 pm DBV Technologies Presents its Half-year Statement of the Liquidity ContractDownload PDF (647 KB) | ||
01/08/2016 - 3:37 pm | Finance DBV Technologies Announces 2016 Financial CalendarDownload PDF (939 KB) | ||
01/07/2016 - 3:39 pm | Finance DBV Technologies Presents its Half-year Statement of the Liquidity ContractDownload PDF (647 KB) | ||
12/10/2015 - 6:29 pm | Science First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)Download PDF (1 MB) | ||
12/07/2015 - 7:00 pm | Clinical | Product Candidates DBV Technologies Announces Initiation of Phase III Study of Viaskin® Peanut for the Treatment of Peanut Allergic ChildrenDownload PDF (1 MB) | ||
11/18/2015 - 7:01 pm | Clinical | Science DBV Technologies to Present Preclinical Data on its Viaskin® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World MeetingDownload PDF (1 MB) | ||
11/12/2015 - 7:02 pm | Clinical DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic EsophagitisDownload PDF (560 KB) | ||
11/03/2015 - 7:04 pm | Corporate | Finance DBV Technologies Reports Interim Financial Results for the third quarter of 2015Download PDF (515 KB) | ||
10/22/2015 - 7:05 pm | Corporate DBV Technologies Announces the Appointment of Michael J. Goller to its Board of DirectorsDownload PDF (1 MB) | ||
10/14/2015 - 7:07 pm | Clinical | Product Candidates DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin MilkDownload PDF (511 KB) | ||
10/05/2015 - 7:08 pm | Clinical | Product Candidates Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic ChildrenDownload PDF (821 KB) | ||
09/11/2015 - 7:09 pm | Corporate | Finance DBV Technologies To Enter SBF 120 IndexDownload PDF (367 KB) | ||
09/08/2015 - 7:10 pm | Conferences DBV Technologies Invited to Present at the Royal Society of Medicine 11th Medical Innovations SummitDownload PDF (356 KB) | ||
09/03/2015 - 7:11 pm | Conferences | Corporate DBV Technologies to Attend Upcoming Investor Conferences and EventsDownload PDF (509 KB) | ||
08/31/2015 - 7:12 pm | General Assembly DBV Technologies’ Extraordinary General Assembly on September 21, 2015Download PDF (942 KB) | ||
08/26/2015 - 10:17 pm | Conferences | Finance DBV Technologies to Attend the Goldman Sachs European Biotech SymposiumDownload PDF (69 KB) | ||
07/28/2015 - 10:18 pm | Corporate | Finance DBV Technologies Reports Financial Results for the First Six Months of 2014Download PDF (187 KB) | ||
07/27/2015 - 7:13 pm | Corporate | Finance DBV Technologies Reports Interim Financial Results for the First Half of 2015Download PDF (659 KB) | ||
07/20/2015 - 7:14 pm | Finance DBV Technologies Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary SharesDownload PDF (499 KB) | ||
07/17/2015 - 10:19 pm | Clinical | Product Candidates DBV Technologies Completes last “food challenge” visit of last PeanutAllergic patient in VIPES Phase IIb Clinical StudyDownload PDF (116 KB) | ||
07/15/2015 - 7:15 pm | Corporate | Finance DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary SharesDownload PDF (501 KB) | ||
07/14/2015 - 7:16 pm | Corporate | Finance DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary SharesDownload PDF (501 KB) | ||
07/08/2015 - 7:17 pm | Science IND Acceptance from FDA for a proof-ofconcept trial using Viaskin® Milk in MilkInduced Eosinophilic Esophagitis in ChildrenDownload PDF (638 KB) | ||
07/02/2015 - 11:30 pm | Corporate | Finance DBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, as well as the filing of its Reference DocumentDownload PDF (649 KB) | ||
07/02/2015 - 6:30 pm | Corporate | Finance Half year update on the DBV Technologies liquidity agreementDownload PDF (199 KB) | ||
06/30/2015 - 7:20 pm | Corporate DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow’s Milk AllergyDownload PDF (641 KB) | ||
06/26/2015 - 7:21 pm | Corporate DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific OfficerDownload PDF (516 KB) | ||
06/23/2015 - 11:00 am | Corporate DBV Technologies’ June 23, 2015 Combined Shareholders’ MeetingDownload PDF (504 KB) | ||
06/23/2015 - 12:00 am | Corporate DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase III Clinical Trial in Children Following Endof-Phase II Meeting with FDA and PIP approval by EMADownload PDF (799 KB) | ||
06/10/2015 - 7:24 pm | Science Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in VaccineDownload PDF (158 KB) | ||
06/08/2015 - 7:25 pm | Conferences | Science DBV Technologies Presents Clinical and Scientific Data at the EAACI CongressDownload PDF (158 KB) | ||
06/04/2015 - 7:27 pm | Corporate | Science DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the Treatment of Peanut Allergic ChildrenDownload PDF (665 KB) | ||
06/02/2015 - 7:28 pm | Conferences | Finance DBV Technologies to Attend Upcoming Investor ConferencesDownload PDF (651 KB) | ||
05/20/2015 - 11:30 am | Corporate Publication of the Resolutions Proposed to the Mixed General Assembly of DBVDownload PDF (1,008 KB) | ||
05/05/2015 - 7:31 pm | Conferences | Corporate | Finance DBV Technologies to Present at Upcoming Investor ConferencesDownload PDF (368 KB) | ||
04/30/2015 - 7:32 pm | Corporate | Finance UNITED STATES SECURITIES AND EXCHANGE COMMISSIONDownload PDF (2 MB) | ||
04/29/2015 - 7:34 pm | Corporate | Finance Topline Financial Results for First Three Months of 2015Download PDF (228 KB) | ||
04/28/2015 - 7:47 pm | Corporate | Finance DBV Technologies Selected to Enter Euronext’s Tech 40 LabelDownload PDF (354 KB) | ||
04/15/2015 - 7:49 pm | Conferences | Corporate | Science DBV Technologies to Present Viaskin® Data at the 2015 EAACI CongressDownload PDF (800 KB) | ||
04/09/2015 - 7:50 pm | Corporate | Product Candidates DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in ChildrenDownload PDF (668 KB) | ||
03/25/2015 - 7:51 pm | Corporate | Finance DBV Technologies Reports Full Year 2014 Financial ResultsDownload PDF (263 KB) | ||
03/10/2015 - 7:52 pm | Corporate DBV Technologies Appoints Daniel Soland to Board of DirectorsDownload PDF (514 KB) | ||
03/06/2015 - 7:53 pm | Conferences | Finance DBV Technologies to Present at Upcoming Investor ConferencesDownload PDF (637 KB) | ||
02/24/2015 - 7:54 pm | Conferences | Science Viaskin® Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food AllergiesDownload PDF (820 KB) | ||
02/13/2015 - 7:56 pm | Corporate | Science DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory BoardDownload PDF (92 KB) | ||
02/03/2015 - 7:57 pm | Conferences | Finance DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)Download PDF (75 KB) | ||
02/03/2015 - 6:30 pm | Conferences | Science Largest Presence Ever of DBV Technologies at 2015 Allergy MeetingDownload PDF (103 KB) | ||
01/29/2015 - 7:30 am | Corporate | Finance DBV Technologies Announces Topline Financial Results for Full Year 2014Download PDF (170 KB) | ||
01/14/2015 - 6:00 pm | Corporate | Finance Half year update on the DBV Technologies liquidity agreementDownload PDF (128 KB) | ||
01/12/2015 - 7:30 am | Science DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of AllergyDownload PDF (120 KB) | ||
01/08/2015 - 7:30 am | Corporate DBV Technologies Provides Organizational UpdateDownload PDF (111 KB) | ||
11/20/2014 - 10:09 pm | Clinical | Product Candidates DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow’s Milk AllergyDownload PDF (105 KB) | ||
10/23/2014 - 10:10 pm | Corporate | Finance Global offering of DBV Technologies ordinary sharesOver-allotment option exercised in full | ||
10/22/2014 - 10:11 pm | Corporate | Finance DBV Technologies S.A. Announces Pricing of Global OfferingDownload PDF (111 KB) | ||
10/20/2014 - 10:13 pm | Corporate | Finance DBV Technologies S.A. Announces Proposed Global OfferingDownload PDF (145 KB) | ||
10/14/2014 - 10:14 pm | Conferences | Finance DBV Technologies Announces Topline Financial Results for First Nine Months 2014Download PDF (83 KB) | ||
09/22/2014 - 10:15 pm | Clinical | Science DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut’s Phase IIb Clinical Trial in Peanut AllergyDownload PDF (149 KB) | ||
07/17/2014 - 10:20 pm | Clinical | Partnership | Product Candidates Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV’s Viaskin® Peanut in Treatment of Peanut AllergyDownload PDF (108 KB) | ||
06/16/2014 - 10:21 pm | Corporate | Finance DBV Technologies to Present at Upcoming US Investors ConferencesDownload PDF (86 KB) | ||
06/10/2014 - 11:35 pm | Conferences | Science Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV’s EPITTM Disease Modifying EffectDownload PDF (116 KB) | ||
05/13/2014 - 11:40 pm | Clinical | Partnership | Product Candidates DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in ChildrenDownload PDF (112 KB) | ||
05/12/2014 - 11:43 pm | Corporate | Finance DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014Download PDF (107 KB) | ||
04/17/2014 - 11:44 pm | Corporate | Finance DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial ReportDownload PDF (137 KB) | ||
04/16/2014 - 11:45 pm | Clinical | Conferences | Product Candidates DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of AllergyCFA 2014 - Clinical Abstract | ||
04/16/2014 - 6:10 am | Clinical | Conferences | Product Candidates CFA 2014 – Clinical AbstractDBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of Allergy | ||
04/15/2014 - 11:46 pm | Corporate | Finance DBV Technologies Announces Topline Financial Results for First Three Months 2014Download PDF (182 KB) | ||
04/09/2014 - 11:48 pm | Corporate | Partnership | Science DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapyDownload PDF (129 KB) | ||
04/07/2014 - 11:49 pm | Corporate DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & StrategyDownload PDF (108 KB) | ||
03/25/2014 - 11:49 pm | Conferences | Science DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014Download PDF (129 KB) | ||
03/17/2014 - 11:51 pm | Clinical | Corporate | Finance DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES UpdateDownload PDF (119 KB) | ||
03/04/2014 - 11:52 pm | Conferences | Science Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying EffectDownload PDF (113 KB) | ||
02/18/2014 - 11:53 pm | Corporate | Partnership | Science DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s DiseaseDownload PDF (134 KB) | ||
01/30/2014 - 11:54 pm | Corporate | Finance DBV Technologies Reports Full Year 2013 Topline Financial ResultsDownload PDF (114 KB) | ||
12/17/2013 - 3:25 pm | Clinical | Corporate | Product Candidates | Science DBV provides 2013 year-end summary and news flow guidance for 2014Download PDF (141 KB) | ||
12/13/2013 - 3:26 pm | Clinical | Conferences | Product Candidates | Science Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization ConferenceDownload PDF (105 KB) | ||
11/26/2013 - 3:28 pm | Corporate | Partnership | Science DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster VaccineDownload PDF (156 KB) | ||
11/14/2013 - 3:29 pm | Corporate | Finance DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investorsDownload PDF (206 KB) | ||
10/24/2013 - 3:30 pm | Clinical | Partnership | Product Candidates NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin® Peanut in the treatment of peanut allergyDownload PDF (117 KB) | ||
10/22/2013 - 3:31 pm | Corporate | Partnership | Science DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A DiseaseDownload PDF (119 KB) | ||
10/18/2013 - 3:34 pm | Clinical | Corporate | Partnership | Product Candidates | Science Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch PollenDownload PDF (154 KB) | ||
10/15/2013 - 3:35 pm | Clinical | Corporate | Finance DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin® PeanutDownload PDF (116 KB) | ||
09/04/2013 - 3:36 pm | Clinical | Product Candidates DBV Technologies initiates a long-term follow-up study of Viaskin PeanutDownload PDF (94 KB) | ||
07/08/2013 - 3:37 pm | Clinical | Product Candidates DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergyDownload PDF (141 KB) | ||
06/28/2013 - 3:38 pm | Conferences | Science DBV Technologies announces breakthrough Data Presentations at EAACI-WAO CongressDownload PDF (84 KB) | ||
06/20/2013 - 3:39 pm | Clinical | Partnership | Product Candidates Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot studyDownload PDF (126 KB) | ||
05/16/2013 - 3:40 pm | Clinical | Partnership | Product Candidates | Science Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergiesDownload PDF (142 KB) | ||
05/07/2013 - 3:41 pm | Corporate | Partnership | Science DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration AgreementDownload PDF (93 KB) | ||
04/25/2013 - 3:42 pm | Corporate | Finance DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial ReportDownload PDF (149 KB) | ||
03/05/2013 - 3:43 pm | Corporate | Finance | Partnership DBV Technologies enters into a strategic manufacturing agreement with SanofiDownload PDF (95 KB) | ||
03/04/2013 - 3:44 pm | Corporate | Finance | Science DBV Technologies reports Full Year 2012 financial results and provides R&D updateDownload PDF (213 KB) | ||
01/31/2013 - 3:45 pm | Clinical | Corporate | Finance | Science DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D ActivitiesDownload PDF (102 KB) | ||
01/15/2013 - 3:46 pm | Corporate | Partnership | Science DBV Technologies and INRA receive funding to develop pediatric bronchiolitis (‘RSV’) vaccine: RSV-NanoViaSkinDownload PDF (172 KB) | ||
12/18/2012 - 7:00 am DBV Technologies’ 2013 Financial calendarDownload PDF (85 KB) | ||
11/14/2012 - 5:20 pm | Clinical | Corporate | Product Candidates | Science DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young childrenDownload PDF (139 KB) | ||
10/16/2012 - 9:46 am | Corporate | Science DBV Technologies and Centre d’Immunologie de Marseille-Luminy (CIML) enter in a Collaboration AgreementDownload PDF (284 KB) | ||
10/15/2012 - 4:00 pm | Corporate | Finance First nine months topline and clinical and business highlightsDownload PDF (131 KB) | ||
08/02/2012 - 5:42 pm | Clinical | Corporate | Product Candidates DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adultsDownload PDF (138 KB) | ||
07/26/2012 - 9:19 am | Clinical | Corporate | Science Half Year 2012 results and R&D highlights: DBV Technologies on trackDownload PDF (140 KB) | ||
07/19/2012 - 5:30 pm | Corporate | Science DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific AdvisorDownload PDF (120 KB) | ||
06/18/2012 - 11:15 am | Clinical | Conferences | Product Candidates DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congressDownload PDF (129 KB) | ||
06/18/2012 - 11:07 am | Clinical | Product Candidates Positive interim clinical data in peanut allergic children treated with VIASKIN PEANUTDownload PDF (333 KB) | ||
05/31/2012 - 11:20 am | Corporate | Science Professor Hugh Sampson joins Scientific Advisory Board of DBV TechnologiesDownload PDF (124 KB) | ||
05/15/2012 - 10:53 am | Clinical | Finance | Science First quarter 2012 topline, scientific activity and upcoming clinical dataDownload PDF (134 KB) | ||
05/10/2012 - 11:01 am | Corporate DBV Technologies welcomes Charles Ruban as Chief Development OfficerDownload PDF (114 KB) | ||
03/28/2012 - 10:28 am | Corporate | Finance Successful Initial Public Offering (IPO) for DBV TechnologiesDownload PDF (401 KB) | ||
02/28/2012 - 9:32 am | Clinical | Product Candidates | Science Viaskin Peanut receives FDA “Fast Track Designation”Download PDF (18 KB) | ||
01/31/2012 - 10:05 am | Corporate | Finance DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiersDownload PDF (501 KB) | ||
12/06/2011 - 10:26 am | Corporate | Finance DBV Technologies introduces its new Chief Financial OfficerDownload PDF (109 KB) | ||
09/21/2011 - 10:32 am | Corporate DBV Technologies moves to BagneuxDownload PDF (201 KB) | ||
06/08/2011 - 9:09 am | Clinical | Science DBV Technologies VIASKIN® technology has been chosen to feature on the cover of the European Journal of Allergy and Clinical Immunology June 2011 issue in its timeline “100 years allergen specific immunotherapy.”Download PDF (2 MB) | ||
01/18/2011 - 10:47 am | Corporate | Science DBV Technologies elects George Horner as non executive ChairmanDownload PDF (181 KB) | ||
01/08/2011 - 9:58 am | Corporate | Science DBV Technologies is very proud to have been chosen to feature on the cover of the Journal of Allergy and Clinical Immunology January 2011 issueDownload PDF (692 KB) | ||
01/05/2011 - 10:57 am | Corporate | Finance DBV Technologies closes $25.5 (€19,4) million Series ‘C’ financing roundDownload PDF (107 KB) | ||
09/23/2010 - 9:52 am | Corporate | Finance | Product Candidates DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®Download PDF (214 KB) | ||
09/01/2010 - 10:00 am | Clinical | Product Candidates VIASKIN® PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization TrialDownload PDF (211 KB) | ||
07/06/2010 - 10:02 am | Clinical | Product Candidates DBV Technologies Receives IND Clearance From FDA to Begin Clinical Trial in Peanut AllergyDownload PDF (207 KB) | ||
06/14/2010 - 10:05 am | Corporate | Science DBV Technologies expands Scientific Advisory Board with appointment of leading US allergy specialistsDownload PDF (205 KB) | ||
12/18/2009 - 12:50 am | Corporate DBV Technologies appoints Professor Robert Zeiger to its Scientific Advisory BoardDownload PDF (208 KB) | ||
10/19/2009 - 12:47 am | Corporate DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory BoardDownload PDF (208 KB) | ||
04/15/2009 - 12:45 am | Corporate | Partnership DBV Technologies signs strategic agreement with Assistance Publique-Hôpitaux de Paris (AP-HP) office of technology transfer and industrial partnershipsDownload PDF (206 KB) | ||
02/19/2009 - 12:40 am | Corporate DBV Technologies expands its Board of DirectorsDownload PDF (202 KB) | ||
01/22/2009 - 11:20 am | Corporate | Finance DBV Technologies raises €6 million in Series B investment and secures new corporate investorDownload PDF (197 KB) | ||
11/13/2007 - 11:23 am | Corporate | Science DBV Technologies Strengthens Board of Directors and Scientific Advisory BoardDownload PDF (211 KB) | ||
01/23/2006 - 11:25 am | Corporate | Finance Sofinnova and Apax Partners invest €12 million in DBV TechnologiesDownload PDF (218 KB) |